TY - JOUR
T1 - Pathogenesis and Treatment of Pruritus in Cholestasis
AU - Kremer, Andreas E.
AU - Beuers, Ulrich
AU - Oude-Elferink, Ronald P. J.
AU - Pusl, Thomas
PY - 2008
Y1 - 2008
N2 - Pruritus is an enigmatic, seriously disabling symptom accompanying cholestatic liver diseases and a broad range of other disorders. Most recently, novel itch-specific neuronal pathways, itch mediators and their relevant receptors have been identified. In addition, new antipruritic therapeutic strategies have been developed and/or are under evaluation. This review highlights recent experimental and clinical findings focusing on the pathogenesis and actual treatment of pruritus in cholestatic liver disease. Evidence-based therapeutic recommendations, including the use of anion exchange resins cholestyramine, colestipol and colesevelam, the microsomal enzyme inducer rifampicin, the opioid receptor antagonists naltrexone and naloxone, and the serotonin reuptake inhibitor sertraline, are provided
AB - Pruritus is an enigmatic, seriously disabling symptom accompanying cholestatic liver diseases and a broad range of other disorders. Most recently, novel itch-specific neuronal pathways, itch mediators and their relevant receptors have been identified. In addition, new antipruritic therapeutic strategies have been developed and/or are under evaluation. This review highlights recent experimental and clinical findings focusing on the pathogenesis and actual treatment of pruritus in cholestatic liver disease. Evidence-based therapeutic recommendations, including the use of anion exchange resins cholestyramine, colestipol and colesevelam, the microsomal enzyme inducer rifampicin, the opioid receptor antagonists naltrexone and naloxone, and the serotonin reuptake inhibitor sertraline, are provided
U2 - https://doi.org/10.2165/00003495-200868150-00006
DO - https://doi.org/10.2165/00003495-200868150-00006
M3 - Review article
C2 - 18840005
SN - 0012-6667
VL - 68
SP - 2163
EP - 2182
JO - Drugs
JF - Drugs
IS - 15
ER -